A groundbreaking collaboration between NeuroOne Medical Technologies Corporation and the University of Minnesota Medical School is paving the way for a transformative approach to treating epilepsy. One that delivers therapies directly to the source of seizures within the brain.
This innovative research focuses on developing a next-generation platform capable of infusing anti-seizure medications precisely into targeted brain regions responsible for seizure activity. By moving beyond traditional systemic drug delivery, this approach aims to significantly improve treatment effectiveness while minimizing unwanted side effects.
Rethinking How We Treat Epilepsy
Epilepsy affects millions worldwide, and for many patients, existing medications fail to fully control seizures or come with challenging side effects. The new approach under development represents a shift toward precision medicine. Treating neurological disorders with highly targeted, individualized therapies.
Using an advanced stereoelectroencephalography (sEEG)-based platform, researchers can both monitor brain activity and deliver therapeutic agents directly to seizure-generating networks. This dual capability opens the door to a more refined understanding of how seizures originate and how they can be disrupted at their source.
From Research to Real-World Impact
The study is led by MnDRIVE scholar, Dr. Sandipan Pati, a leading expert in epilepsy care and research. Initial work will begin in large animal models to evaluate safety, feasibility, and physiological effects. If successful, the program is expected to advance toward human clinical trials. Providing a promising therapy one step closer to patients.
By delivering medication directly into the brain, researchers aim to:
- Increase therapeutic precision
- Reduce systemic toxicity and off-target effects
- Improve outcomes for patients with drug-resistant epilepsy
A New Era of Brain-Directed Therapy
This collaboration reflects a broader movement toward minimally invasive, targeted neuromodulation and drug delivery technologies. The University of Minnesota has long been at the forefront of epilepsy research, integrating engineering, neuroscience, and clinical care to develop personalized treatment strategies.
If successful, this approach could redefine how epilepsy is treated. Shifting from generalized medication strategies to a highly localized, brain-directed therapies tailored to each patient’s unique neural network.
As this research progresses, it represents more than a technological advancement. It offers new hope for individuals living with epilepsy and underscores the power of collaborative innovation in transforming neurological care.
